







Active Biotech: Teva Completes Enrollment in Laquinimod Phase III Clinical Trial
Published in Science and Technology on Tuesday, November 18th 2008 at 1:23 GMT by Market Wire

LUND, SWEDEN--(Marketwire - November 18, 2008) -
- Recruitment Still Ongoing For Second, Pivotal Phase III Study, Bravo -
Jerusalem, Israel and Lund, Sweden, November 18, 2008 - Teva Pharmaceutical Industries Ltd. (
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on November 18, 2008, at 8:00 a.m.
Contact: Elana Holzman, Teva Pharmaceutical Industries Ltd., +972 3 926-7554 Kevin Mannix, Teva North America, +1 215 591-8912 Tomas Leanderson, Active Biotech AB, +46 46 19 20 95 Göran Forsberg, Active Biotech AB, +46 46 19 11 54
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Teva Completes Enrollment in Laquinimod Phase III Clinical Trial: [ http://hugin.info/1002/R/1270575/281461.pdf ]
Copyright © Hugin AS 2008. All rights reserved.